Further advances in the synthesis of endocannabinoid-related ligands Anu MahadevanRaj K. Razdan OriginalPaper Article: 50
Challenges in the transition to model-based development Thaddeus H. GraselaJill Fiedler-KellyCharles W. Dement OriginalPaper Article: 49
Population pharmacokinetic studies in pediatrics: Issues in design and analysis Bernd MeibohmStephanie LäerJeffrey S. Barrett OriginalPaper Article: 48
Evidence of effectiveness: How much can we extrapolate from existing studies? Howard LeeDong-Seok YimCarl C. Peck OriginalPaper Article: 47
Pharmacodynamic parameter estimation: Population size versus number of samples Suzette GirgisSudhakar M. PaiVijay K. Batra OriginalPaper Article: 46
A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective Janet R. WadeMonica EdholmTomas Salmonson OriginalPaper Article: 45
Neuropeptide-processing enzymes: Applications for drug discovery Lloyd D. Fricker OriginalPaper Article: 44
Homology modeling of opioid receptor-ligand complexes using experimental constraints Irina D. PogozhevaMagdalena J. PrzydzialHenry I. Mosberg OriginalPaper Article: 43
Serotonin transporters: Implications for antidepressant drug development Kellie J. WhiteCrystal C. WallineEric L. Barker OriginalPaper Article: 42
A pragmatic approach to the design of population pharmacokinetic studies Amit RoyEne I. Ette OriginalPaper Article: 41
Modeling and simulation of adherence: Approaches and applications in therapeutics Leslie A. KennaLine LabbéMarc Pfister OriginalPaper Article: 40
Population pharmacokinetics/pharmacodynamics of anesthetics Erik OlofsenAlbert Dahan OriginalPaper Article: 39
Recommended reading in population pharmacokinetic pharmacodynamics Peter L. Bonate OriginalPaper Article: 37
Population pharmacokinetics: A memorial tribute to Lewis Sheiner Diane R. MouldPeter L. Bonate EditorialNotes Article: 36
DARPP-32 mediates the actions of multiple drugs of abuse Per SvenningssonAngus C. NairnPaul Greengard OriginalPaper Article: 35
Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP Nurulain ZaveriFaming JiangLawrence Toll OriginalPaper Article: 34
Editorial: Theme issue “Drug addiction—From basic research to therapies” Rao S. RapakaWolfgang Sadée EditorialNotes Article: 33
Challenges with the development and approval of pharmaceuticals for fish Susan Storey OriginalPaper Article: 32
Use of anatomical and kinetic models in the evaluation of human food additive safety William L. Roth OriginalPaper Article: 31
Fish drug analysis—Phish-pharm: A searchable database of pharmacokinetics data in fish Renate ReimschuesselLeslie StewartClifford Hodsdon OriginalPaper Article: 30
The joint food and agriculture organization of the united nations/world health organization expert committee on food additives and its role in the evaluation of the safety of veterinary drug residues in foods James D. MacNeil OriginalPaper Article: 28
Postexposure management and treatment of anthrax in dogs—Executive councils of the American academy of veterinary pharmacology and therapeutics and the American college of veterinary clinical pharmacology Cory Langston OriginalPaper Article: 27
Challenges and issues in veterinary pharmacology and animal health 2004—Preface Marilyn MartinezStefan Soback EditorialNotes Article: 26